SCHEMBL12040694

SCHEMBL12040694

Cc1cc(S(=O)(=O)Nc2cccnc2C(=O)c2ncnc3[nH]ccc23)ccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.62
CYP3A4 P08684 3/20 0.62
CYP2C9 P11712 2/20 0.59
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
TNNI3K Q59H18 7/20 0.46
BRAF P15056 2/20 0.46
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.40
HSP90AA1 P07900 1/20 0.40
RAB9A P51151 1/20 0.40
ADAM17 P78536 1/20 0.40
KLF5 Q13887 1/20 0.40
SLC40A1 Q9NP59 1/20 0.40
CYP2C19 P33261 1/20 0.38
CCR4 P51679 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12040697 0.87 CYP2C9 (0.77) CCR2CYP3A4CYP2C9MEN1KMT2A
SCHEMBL12040688 0.87 CYP3A4 (0.80) CCR2CYP3A4CYP2C9MEN1KMT2A
SCHEMBL1188125 0.87 CYP2C9 (0.79) CCR2CYP3A4CYP2C9LMNA
SCHEMBL12040691 0.84 CYP2C9 (0.59) CCR2CYP3A4CYP2C9MEN1KMT2A
SCHEMBL12040687 0.82 CYP3A4 (0.63) CCR2CYP3A4CYP2C9MEN1KMT2A
SCHEMBL127931 0.81 CCR2 (0.81) CCR2CYP3A4CYP2C9TNNI3KBRAF
SCHEMBL12040686 0.79 CYP3A4 (0.72) CCR2CYP3A4CYP2C9TNNI3KBRAF
SCHEMBL12594276 0.77 CCR2 (0.65) CCR2CYP3A4CYP2C9
Ilacirnon SCHEMBL127113 0.77 CCR2 (1.00) CCR2CYP3A4CYP2C9TNNI3KBRAF
Ilacirnon SCHEMBL31378455 0.77 CCR2 (1.00) CCR2CYP3A4CYP2C9TNNI3KBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745312-B2 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation CHEMOCENTRYX, INC. (US) 2017-08-29 US disclosed
US-20170022205-A1 FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION CHEMOCENTRYX, INC. (US) 2017-01-26 US disclosed
US-9394307-B2 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation CHEMOCENTRYX, INC. (US) 2016-07-19 US disclosed
US-8546408-B2 Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation CHEMOCENTRYX, INC. (US) 2013-10-01 US disclosed
US-20110319433-A1 FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION CHEMOCENTRYX, INC. 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022205-A1 FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION CCR2, CXCR2, CX3CR1 CCR2 1/4885CYP3A4 1134/4885CYP2C9 1281/4885
US-20110319433-A1 FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREATMENT OF INFLAMMATION CCR2, CXCR2, CX3CR1 CCR2 1/4885CYP3A4 1134/4885CYP2C9 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.